Willer DO, Oostvogels L, Cunningham AL, et al. - In this post-hoc analysis, recombinant zoster vaccine's (RZV) effectiveness against herpes zoster (HZ) and postherpetic neuralgia (PHN) was determined by sex, geographic region, and geographic ancestry/ethnicity in ≥ 50-year-olds (ZOE-50: NCT01165177) and ≥ 70-year-olds (pooled data from ZOE-50 and ZOE-70: NCT01165229). Participants were administered 2 doses of adjuvanted RZV or placebo, intramuscularly, 2 months apart, in 2 randomized clinical trials. Both men and women demonstrated similar efficacy of the vaccine against HZ or PHN. Regardless of gender, region, or geographic ancestry/ethnicity, RZV seemed to be effective against HZ and PHN, though the ZOE-50/70 investigations were not powered or pre-designed for these post-hoc analyses.